(Q35080295)

6 August 2017

1 reference

title

Study of suboptimum treatment response: lessons from breast cancer (English)

1 reference

6 August 2017

1 reference

1

Per Eystein Lønning

1 reference

6 August 2017

1 March 2003

1 reference

Lancet Oncology Commission

6 August 2017

1 reference

6 August 2017

4

1 reference

6 August 2017

177-185

1 reference

6 August 2017

3

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The value of progesterone receptor assays in the management of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Translational research: what is it?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

From translational research to improved local control and survival: the Gilbert Fletcher Award Lecture, Lugano, March 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The relationship between prognostic and predictive factors in the management of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Prognostic value of estrogen receptors in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Relationship between proliferative activity and estrogen receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Mechanisms of p53-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Assessment of response to therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

p53 is associated with cellular microtubules and is transported to the nucleus by dynein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Transcriptional activities of p73 splicing variants are regulated by inter-variant association.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Assessing TP53 status in human tumours to evaluate clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

DNA microarrays identification of primary and secondary target genes regulated by p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Delineation of prognostic biomarkers in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Prediction of central nervous system embryonal tumour outcome based on gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Gene-expression profiles predict survival of patients with lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Molecular classification of cutaneous malignant melanoma by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

The microarray way to tailored cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

High-fidelity mRNA amplification for gene profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Gene expression profiles in normal and cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901022-2

7 January 2021

10.1016/S1470-2045(03)01022-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12623363